Infection rates were consistently lower in adults with neuromyelitis optica spectrum disorder (NMSOD) treated with Enspryng (satralizumab-mwge) over other immunosuppressive therapies, according to long-term data from clinical trials and real-world settings. “This analysis provides reassurance that the [Enspryng] safety profile observed in patients with NMOSD in a clinical…
Enspryng (satralizumab-mwge)
Nearly all neuromyelitis optica spectrum disorder (NMOSD) patients who start taking Enspryng (satralizumab) are free of relapses after six months, according to interim data from an ongoing post-marketing surveillance study in Japan. With a relapse rate of only 5% over six months, the findings were “comparable or lower…
Enspryng (satralizumab-mwge) promotes an anti-inflammatory profile in plasmablasts, the immune cells that produce large amounts of the self-reactive antibodies that drive most cases of neuromyelitis optica spectrum disorder (NMOSD). That’s according to a study analyzing immune cells from NMOSD patients before and after treatment with Enspryng, as well…
Up to 4.6 years of treatment with Enspryng (satralizumab) continues to safely reduce relapse rates and prevent disability progression for people with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against aquaporin-4 (AQP4). That’s according to pooled data from the Phase 3 SAkuraSky (NCT02028884) and…
Since 2012, I have been using Rituxan (rituximab) to treat my neuromyelitis optica. I had no major complaints about it until 2018. My neurologist back then referred me to an immunologist, who recommended I start immunoglobulin replacement therapy (IVIG) to increase the levels of immunoglobulins that had been…
When I was diagnosed with neuromyelitis optica (NMO) in 2012, the U.S. Food and Drug Administration (FDA) hadn’t yet approved any medications specifically to treat this disease. However, doctors could select various therapies to help patients prevent or deal with attacks. When NMO patients had an attack, doctors treated…
Recent Posts
- Global study finds genetic signature in blood that identifies NMOSD
- Suddenly, seemingly out of nowhere, I found a sense of empowerment
- Soliris reduces relapse rates in AQP4-positive NMOSD patients: Study
- The pain of NMOSD nerve sensitivity means more than just a cold shoulder
- Most adults with NMOSD use biologic therapies: Registry study